#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3734283	B	Inhibition of human GRK2 after 90 to 120 mins by Kinase-Glo assay	Homo sapiens	97		single protein format	Patent Bioactivity Data
2.	ALA3734284	B	Inhibition of GRK3 (unknown origin) after 90 to 120 mins by Kinase-Glo assay	Homo sapiens	24		single protein format	Patent Bioactivity Data
3.	ALA3734285	B	Inhibition of GRK5 (unknown origin) after 90 to 120 mins by Kinase-Glo assay	Homo sapiens	24		single protein format	Patent Bioactivity Data
4.	ALA3734286	B	Inhibition of GRK6 (unknown origin) after 90 to 120 mins by Kinase-Glo assay	Homo sapiens	10		single protein format	Patent Bioactivity Data
5.	ALA3734288	F	Antiglaucoma activity in cat assessed as decrease of hyperemia administered topically	Felis catus	1		organism-based format	Patent Bioactivity Data
6.	ALA3734289	B	Inhibition of GRK2 in human U2OS cells assessed as inhibition of isoproterenol-induced translocation of arrestin-GFP to beta 2 adrenergic receptor preincubated for 60 mins by Transfluor assay	Homo sapiens	1		cell-based format	Patent Bioactivity Data
7.	ALA3734290	B	Inhibition of GRK2 in human U2OS cells assessed as inhibition of isoproterenol-induced translocation of arrestin-GFP to beta 1 adrenergic receptor preincubated for 60 mins by Transfluor assay	Homo sapiens	1		cell-based format	Patent Bioactivity Data
8.	ALA3734291	B	Inhibition of GRK2 in human U2OS cells assessed as inhibition of morphine-induced translocation of arrestin-GFP to mu opioid receptor preincubated for 60 mins by Transfluor assay	Homo sapiens	1		cell-based format	Patent Bioactivity Data
9.	ALA3734292	B	Inhibition of GRK2 in HEK293 cells overexpressing beta 2 adrenergic receptor assessed as increase in c-AMP accumulation in presence of isoproterenol	Homo sapiens	1		cell-based format	Patent Bioactivity Data
10.	ALA3734297	F	Antiglaucoma activity in cat assessed as decrease of redness administered topically	Felis catus	1		organism-based format	Patent Bioactivity Data
11.	ALA3734298	F	Antiglaucoma activity in cat assessed as decrease of ocular irritation administered topically	Felis catus	1		organism-based format	Patent Bioactivity Data